Artelo Biosciences, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ARTL Nasdaq 2834 www.artelobio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Artelo Biosciences, Inc.

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer - Nov 4th, 2025 6:30 am
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer - Oct 27th, 2025 6:00 am
Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit - Oct 15th, 2025 7:15 am
Artelo Biosciences Announces Closing of $2.0 Million Public Offering - Oct 1st, 2025 2:05 pm
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering - Sep 30th, 2025 6:30 am
Artelo Biosciences Announces Proposed Underwritten Public Offering - Sep 29th, 2025 5:15 pm
Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference - Sep 29th, 2025 6:30 am
Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms - Sep 10th, 2025 6:30 am
Alphabet downgraded, Boeing upgraded: Wall Street's top analyst calls - Sep 8th, 2025 7:49 am
Artelo Biosciences Announces Closing of $3.0 Million Public Offering - Sep 5th, 2025 2:05 pm
Wall Street Weighs Payrolls, Jobless Claims Data, Driving Muted Premarket Action for US Equity Futures - Sep 4th, 2025 7:08 am
Artelo Biosciences Announces Pricing of $3.0 Million Public Offering - Sep 4th, 2025 6:37 am
Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results - Sep 3rd, 2025 9:33 am
Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS) - Sep 3rd, 2025 6:45 am
Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain - Aug 25th, 2025 5:55 am
Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results - Aug 13th, 2025 6:00 am
Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13 - Aug 11th, 2025 7:15 am
Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression - Aug 1st, 2025 5:45 am
Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium - Jul 9th, 2025 5:50 am
Artelo Biosciences’ ART12.11 Shows Promising Antidepressant Effects in Preclinical Study - Jul 9th, 2025 5:20 am